The proportion of participants achieving HbA1c DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head comparison with semaglutide in ...

Midlife weight gain is a persistent challenge for many women, but emerging research suggests hormone therapy may enhance response to glucagon-like peptide-1 (GLP-1)–based treatments.

Development of the latest class of incretin-based therapeutics for diabetes and obesity has been heralded as a major step ...

Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Why is the Supreme Court’s directive to notify a new Saranda wildlife sanctuary important for your UPSC exam? What ...

The cornerstone of this strategic offensive is the drug Tirzepatide, a compound already achieving blockbuster status in other global markets for treating Type 2 diabetes and obesity. Under the brand ...

Cipla has partnered with Eli Lilly and Company (India) to distribute & promote Tirzepatide in India under a second brand name, Yurpeak, aiming to expand access to innovative treatments for chronic ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

Shares of Cipla fell more than 3 per cent on Friday after the drugmaker announced a partnership with US pharmaceutical major ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Brokerage firm Nuvama Institutional Equities believes Cipla, with its strong field force and distribution network, could ...